Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hizentra in adults with dermatomyositis
2018-003171-35Phase 3Active
- Sponsor
- CSL Behring
- Start
- Sep 2019
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in dermatomyositis (DM) comparing Hizentra with Placebo (2 arms). Primary endpoint: Responder rate. Started Sep 2019; status: active.
02
Drugs
polyvalent human immunoglobulin
03
Conditions
dermatomyositis (DM)
Beyond the preview
Go deeper on 2018-003171-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003171-35.